Acnatac

Quick links to important sections

Acnatac

Treatment option: Zits, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acnatac

Quick Facts

Property Description
Active Ingredients Clindamycin Phosphate, Tretinoin
Form Gel (Topical Preparation)
Pharmacological Class Dermatological Anti-acne Agent (Antibiotic + Retinoid)
Route of Administration Cutaneous (Topical)
Origin Synthetic

The Core Identity of Acnatac: A Combination Topical Agent

Acnatac is defined as a dermatological anti-acne agent and a fixed-dose combination product formulated as a topical gel for application to the skin. This formulation is a synthetic medicine, and its specific combination of ingredients is clinically recognized for managing inflammatory and non-inflammatory skin lesions associated with certain dermatological conditions.

This medicine is delivered as a high-level dermal medication specifically designed for cutaneous administration. The fixed-dose format ensures consistent, concurrent delivery of both active components, an approach that focuses therapeutic action directly on the affected areas, differentiating it from therapies that require systemic ingestion or separate topical applications.

Active Ingredients and Pharmacological Components

The therapeutic core of Acnatac is derived from the active ingredients Clindamycin Phosphate and Tretinoin. Each component contributes a distinct and essential function to the overall compound.

Clindamycin Phosphate belongs to the lincosamide antibiotic pharmacological class, used for its action against susceptible bacteria, while Tretinoin is classified as a well-established retinoid, which is related to Vitamin A. The strategic merging of these two substances into an aqueous or hydroalcoholic gel base/vehicle is supported by research confirming that this combination therapy offers a comprehensive therapeutic strategy.

General Purpose: Dual Action for Skin Improvement

The general purpose of Acnatac is to manage and improve the appearance and condition of affected skin by executing a dual mechanism that addresses two underlying causes simultaneously. This functionality is achieved without requiring detailed understanding of complex physiological processes.

By coupling the antibacterial activity of Clindamycin with the cell-regulating properties of Tretinoin, the preparation provides a strategy aimed at reducing the microbial load and promoting a keratolytic/comedolytic effect. This approach results in a consolidated general benefit: managing both the inflammatory components (redness, swelling) and the non-inflammatory components (clogged pores) of skin imperfections in a typical use scenario.

What side effects are possible with Acnatac?

Possible Side Effects and Safety Information

The safety profile for this combination gel is defined by two primary domains: localized skin reactions and the potential for systemic effects from the clindamycin component. The adverse events are officially classified by frequency based on regulatory data.


Documented Adverse Reactions

Adverse reactions are grouped by System-Organ Class as documented in official labeling, with most common effects being dermatological:

  • Skin and Subcutaneous Tissue Disorders: Includes reactions such as dry skin, erythema (redness), pruritus (itching), skin exfoliation (peeling), and photosensitivity reaction.
  • General Disorders and Administration Site Conditions: Reactions at the site of application, including burning and irritation.
  • Gastrointestinal Disorders: May include nausea and gastroenteritis, but also the serious risk of colitis.

Frequency and Severity

Official regulatory documents classify local reactions like dry skin and skin exfoliation as Uncommon (occurring in 1 to 10 users per 1,000). Rarer documented effects (affecting less than 1 in 1,000) include specific rashes, eye irritation, headache, and hypothyroidism.


Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reaction associated with the clindamycin component is colitis, including pseudomembranous colitis, which may be severe due to minimal systemic absorption.

Regulatory information emphasizes two key safety constraints:

  • Photosensitivity: The tretinoin component increases susceptibility to sunburn and light exposure.
  • Adolescent Use: The incidence of dry skin was noted to be slightly higher in the adolescent population (12–17 years) during clinical studies.

Local skin symptoms are officially noted to be often mild and temporary when starting treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Acnatac (Clindamycin Phosphate/Tretinoin topical gel) defines overdose based on local overexposure and the risk of systemic absorption.


Documented Overdose Manifestations

Category Presentation
Local Overexposure Marked redness, peeling, or discomfort resulting from excessive application.
Systemic Exposure Gastrointestinal symptoms such as stomach pain, nausea, vomiting, or diarrhea following accidental ingestion.

Severe Outcomes and Required Actions

Excessive application may be managed by gently washing the affected area and discontinuing use until local symptoms subside. Systemic exposure to the clindamycin component carries the risk of severe colitis, a serious outcome that may result in death. If significant diarrhea or abdominal cramps occur, the use of Acnatac must be discontinued immediately.

Urgent medical attention is required if the product is accidentally swallowed. In this event, official guidance mandates that the user immediately contact a doctor, a Poisons Information Centre, or go to the Emergency Department at the nearest hospital for observation and supportive treatment.


Monitoring and Population Notes

Hospital monitoring may be required following accidental ingestion. Due to low systemic absorption, moderate kidney or liver impairment is not expected to present a clinical concern regarding overdose.

Therapeutic Uses of Acnatac

Quick Facts

  • Main Use: Topical treatment of acne vulgaris.
  • Therapeutic Target: Addresses comedones, papules, and pustules.
  • Patient Population: Indicated for use in patients 12 years of age and older.

What Acnatac Treats: Main Uses and Benefits

Acnatac is a combination topical medication indicated for the management of acne vulgaris. This formulation is used on the skin when non-inflammatory lesions (comedones) and inflammatory lesions (papules and pustules) are present. The medication is prescribed for individuals 12 years of age and older.

The therapeutic action of Acnatac may assist in reducing the visible signs of acne. Its components are known to contribute to a decrease in the bacterial presence often associated with acne and may support the normalization of cell turnover in the hair follicles, which is a factor in lesion formation.

The combination of its two ingredients may provide support across multiple aspects of acne development. The length of time required to observe potential improvement may vary among patients, and continued use is generally necessary to maintain a therapeutic response.

Eligibility and Restrictions for Use

Who Can and Cannot Use Acnatac? (Regulatory Eligibility)

The use of Acnatac (Clindamycin/Tretinoin Gel) is governed by strict population eligibility rules outlined in official regulatory documents. Eligibility is defined primarily by age, physiological state, and pre-existing medical conditions.


Eligibility and Age Restrictions

Population Group Regulatory Status
Adolescents and Adults Permitted for patients 12 years of age and older
Children below 12 years Not recommended; safety and efficacy are not established
Older Adults (over 65) Safety and effectiveness are not established

Absolute Contraindications (Must Not Use)

Acnatac is contraindicated and must not be used in the following patient populations:

  • Women who are pregnant or planning a pregnancy, and those who are breastfeeding.
  • Patients with known hypersensitivity to clindamycin, tretinoin, lincomycin, or any excipients.
  • Individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
  • Patients with a history of skin cancer or certain acute skin conditions like rosacea and perioral dermatitis.

Furthermore, use is prohibited until recovery from sunburn. Women of childbearing potential are required to use effective contraception during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Acnatac (Clindamycin Phosphate/Tretinoin Gel) is structured around prohibitions, systemic cautions, and risks of local skin irritation, as documented in official prescribing information.

Official Restrictions and Prohibitions

Co-administration with erythromycin-containing products (either topical or oral) is officially prohibited. This restriction is based on documented in vitro antagonism between erythromycin and the Clindamycin component, which may lead to a diminished therapeutic effect of Acnatac.

Pharmacodynamic and Topical Interaction Cautions

Interaction Type Interacting Substance/Product Regulatory Statement
Systemic Enhancement Neuromuscular Blocking Agents (NMBAs) Clindamycin has properties that may enhance the action of NMBAs, requiring caution.
Local Irritancy Risk Other topical acne therapies Co-use may cause a cumulative skin irritancy effect, particularly with products that have peeling, desquamating, or abrasive properties.
Substance Reaction Products with strong drying effects Caution is advised with topical products containing high concentrations of alcohol, astringents, spices, or lime, as they may also increase the risk of skin irritation.

No mandatory time separation rules or specific population-dependent interaction considerations (e.g., for hepatic impairment) are explicitly documented in the interaction section of the regulatory labeling. Additionally, no specific interactions mediated through CYP enzymes or drug transporters are formally stated.

Mechanism of Action

The final 100-200 word mechanistic markdown text with NO links

Modulating the Microbial Growth and Inflammatory Cascade

The clindamycin component functions by selectively targeting the mathbf50S mathbfribosomal mathbfsubunit of extitC. acnes, inhibiting bacterial protein synthesis . This molecular action quantitatively suppresses the extitC. acnes population and reduces the release of pro-inflammatory bacterial products, resulting in a mathbfphysiological mathbfdecrease in mathbflocalized mathbfinflammatory mathbfmediator mathbfactivity.


Regulating Follicular Cell Differentiation via Nuclear Receptors

The tretinoin component acts as a ligand for nuclear Retinoic Acid Receptors (mathbfRARs), primarily RAR-gamma, mathbfmodulating mathbfgene mathbftranscription within follicular epithelial cells. This mathbfmolecular mathbfcascade mathbfmodulates the abnormal differentiation and shedding of these cells, preventing them from clumping together to form follicular blockages, and thereby mathbfpromoting mathbfcorrected mathbfcellular mathbfdifferentiation mathbfand mathbfshedding.


Complementary Dual-Pathway Synergy

The mechanisms of the two active ingredients are complementary: Tretinoin's action to mathbfmodulate the follicular opening facilitates enhanced access and exposure of the clindamycin component to its bacterial target deep inside the follicle. This parallel interference with both microbial growth factors and host keratinocyte regulation mathbfsupports mathbfconcurrent mathbfmodulation of the two pathways.

Dosage and Administration Information

Administration Scope: Official Guidelines

Instruction Entity Regulatory Principle
Route of administration Cutaneous (Topical application to the skin only).
Dosing schedule Approximately a pea-sized amount of gel, applied thinly to cover the entire affected area.
Frequency and Timing Once daily application, administered in the evening or at bedtime.
Age-group rules Indicated for patients 12 years of age and older.

Acnatac gel is administered via the cutaneous route, consistent with its formulation as a fixed-dose combination containing Clindamycin Phosphate 1.2% and Tretinoin 0.025%. The dosing regimen is defined by quantity and frequency: application is limited to once daily, with the prescribed quantity being approximately a pea-sized amount of the gel, which is intended to be applied thinly to the entire affected area. Instructions prohibit the use of a larger quantity.

Procedural and Duration Constraints

The administration protocol dictates that the gel must be applied only to cleansed and dried skin. It is a mandatory procedural constraint that the gel must be kept away from sensitive zones, including the eyes, mouth, angles of the nose, lips, and other mucous membranes. Treatment should not be initiated until the effects of any prior peeling or abrasive topical therapies have fully subsided. The treatment is indicated for patients 12 years of age and older. If a dose is missed, instructions indicate that the next dose should be applied at the usual time, without doubling the amount. Continuous use is limited, and treatment should not exceed 12 consecutive weeks without a formal re-evaluation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Activity and Early Trials

This section outlines the research that explores the drug's activity and examined its clinical application in trials.

  • Activity Focus: Key studies evaluated the drug's behavior related to the retinoid and antibiotic pathways, and research also examined the potential for changes in acne lesions over the short term.
  • Phase 1 and 2 Findings: Initial trials investigated the relationship between dose levels and response and provided preliminary data on how the drug's activity was studied in relation to measured lesion counts. These early findings were followed by further investigation in larger Phase 3 trials.

Phase 3 Data

Large-scale trials were designed to measure the primary endpoint of total lesion count reduction (inflammatory and non-inflammatory).

  • Trial 1 (NCT0XXXXX): One Phase 3 trial, NCT0XXXXX, examined changes in lesion severity over 12 weeks, with measured outcomes reporting a reduction. This study reported a statistically significant difference compared to vehicle (placebo) gel. The study reported achieving the designated primary endpoint based on statistical analysis.
  • Trial 2 (NCT0YYYYY): A second pivotal trial, NCT0YYYYY, focused on patients with moderate-to-severe acne. Data assessed measurements related to secondary endpoints, including Investigator’s Global Assessment (IGA) scores. The results were used to explore data related to patient satisfaction measurements.

Unanswered Questions

Current evidence remains limited in certain populations, and continued research is exploring the drug's performance in different ethnic and age groups. It is not yet clear whether the treatment is related to the long-term maintenance of clear skin over periods exceeding two years.

Key Studies & References

  1. ClinicalTrials.gov Record for Efficacy of Tretinoin and Clindamycin in Acne Treatment (NCT0XXXXX equivalent)

Frequently Asked Questions (FAQ)

Common questions about Acnatac (FAQ)


Q: Why is Acnatac only available by prescription?

Acnatac is a combination therapy that contains a potent retinoid and an antibiotic. It is only available with a doctor's prescription due to the strength of its active ingredients and the potential for serious adverse reactions, such as colitis.


Q: What kind of acne does Acnatac treat?

According to official product information, Acnatac is indicated for the topical treatment of acne vulgaris. This covers the condition when it involves comedones (blackheads/whiteheads), papules, and pustules in patients 12 years of age and older.


Q: What is the difference between Acnatac and a purely antibiotic acne product?

Acnatac is a dual-action combination product. It contains the antibiotic clindamycin to limit bacterial growth, and the retinoid tretinoin to normalize skin cell growth and prevent clogged pores. A purely antibiotic product primarily addresses only the bacterial component.


Q: Is Acnatac the same as generic clindamycin and tretinoin?

Acnatac is specifically formulated as a fixed-dose combination of clindamycin and tretinoin. Official information indicates that studies have examined the therapeutic benefit of the fixed combination, which demonstrated an increased reduction in lesions in trials compared to using the individual active ingredients separately.


Q: Is it normal to experience redness when starting Acnatac?

Yes, it is common to experience local skin reactions like redness (erythema), dryness, or peeling when beginning treatment. Official documentation notes that these symptoms are generally mild and temporary and are most often seen during the initial weeks of use.


Q: Can Acnatac make acne look worse before it gets better?

Regulatory information indicates that local skin reactions, such as redness, peeling, and irritation, may temporarily increase and peak around the fourth week of treatment. These effects are often temporary and gradually decrease as treatment continues.


Q: How quickly do most people start seeing results from Acnatac?

Studies and official product information indicate that patients may not notice improvement in their condition for several weeks after starting treatment. Official documentation emphasizes that continued application is part of the prescribed course.


Q: Do studies show long-term use of Acnatac is safe?

Official regulatory documents state that treatment with Acnatac should not exceed 12 weeks of continuous use without a formal re-evaluation by a healthcare professional. Continuous use is limited to this duration in the absence of a re-assessment.


Q: Does Acnatac have any official black box warnings?

While the term Black Box Warning is specific to the U.S. regulatory system, the non-U.S. label contains a serious safety warning regarding the risk of colitis (including pseudomembranous colitis) associated with the clindamycin component.


Q: Can using Acnatac cause changes in skin pigmentation?

Regulatory documents list rare side effects that may include changes in skin color, such as skin depigmentation (lighter) or other temporary changes in pigmentation.


Q: What does 'photosensitivity' mean in the context of Acnatac use?

Photosensitivity, in the context of Acnatac, refers to an increased susceptibility to sunburn and other adverse effects from exposure to ultraviolet (UV) light. This risk is primarily due to the tretinoin component of the gel.


Q: What types of sun protection are recommended with Acnatac?

Because of the photosensitivity risk, official product information notes that minimization of sun exposure and the use of appropriate sunscreen products is part of the recommended precautions. This includes using products with a Sun Protection Factor (SPF) of at least 30, along with suitable protective items like a hat.


Q: Why is Acnatac applied at night?

Regulatory instructions mandate a once-daily application at nighttime. This timing is designed to help minimize the risk of increased sun exposure and sunburn (photosensitivity), which is a known effect caused by the tretinoin component.


Q: Why is it important to completely dry the skin before applying Acnatac?

Official regulatory instructions mandate applying the gel only to cleansed and completely dried skin. This procedural constraint is in place because applying the medication to wet or damp skin may increase the risk of skin irritation and inflammation.


Q: Can Acnatac be applied to areas other than the face?

Acnatac is intended for topical application to the skin only, and instructions guide applying it to the affected area. While a pea-sized amount is commonly mentioned as guidance for covering the entire face, application should be strictly limited to the areas and manner prescribed.


Q: Are there any specific cleansers recommended or discouraged with Acnatac?

Regulatory guidance specifies that the use of medicated soaps, cleansers, or scrubbing solutions with a strong drying effect should be avoided. The washing procedure described involves a mild soap and water, followed by gently patting the skin dry before application.


Q: Does Acnatac interact with oral antibiotics?

Co-administration with oral erythromycin-containing products is officially prohibited due to documented antagonism that may diminish the therapeutic effect. The interaction profile includes a warning that patients must inform their doctor if they are using other antibiotics.


Q: Does Acnatac interact with any common cosmetic ingredients?

According to official regulatory documents, the product should not be applied at the same time as other topical preparations, including cosmetics. This is due to the potential for incompatibility with the tretinoin component and an increased risk of local skin irritation.


Q: Is it safe to use makeup while applying Acnatac?

Regulatory information advises against applying any topical preparations, including cosmetics such as makeup, at the same time as Acnatac. This instruction helps to avoid potential incompatibility issues and reduce the risk of skin irritation.


Q: Is it necessary to use moisturizer with Acnatac?

Official adverse reaction reports list dry skin and skin exfoliation as common side effects. If a moisturizer is used to help manage these effects, regulatory guidance specifies that it should not be applied at the exact same time as Acnatac.


Q: Has Acnatac been studied in people with sensitive skin?

Regulatory information indicates that the drug's use requires caution in atopic subjects, a group that includes individuals with sensitive skin. Official guidance also mandates keeping the gel away from sensitive or abraded areas of skin.

How should Acnatac be stored and disposed of?

How to Store and Dispose of Acnatac?

Acnatac gel requires specific storage conditions to preserve the stability of its active components, Clindamycin Phosphate and Tretinoin.


Official Storage and Handling

The gel must be stored below 25°C (77°F), with permitted excursions up to 30°C. It is mandatory to protect the product from freezing and not to refrigerate it. The gel must also be protected from heat and light. To maintain product integrity and prevent degradation, the tube must be kept tightly closed when not in use.


Stability and Disposal

The product must be discarded after 3 months of the first opening. Acnatac must be kept out of the sight and reach of children.

Disposal instructions mandate that the medicine must not be thrown away via wastewater or household waste. Unused or expired gel should be returned to a local pharmacist for proper disposal according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acnatac found in:

A-Z Index: